Featured Press Releases

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Vertex Shares New Data on ALYFTREK® Benefits and Sweat Chloride Reduction

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

Formosa licenses Clobetasol Propionate Ophthalmic Suspension to Apotex for ocular surgery relief

  • 05 Aug 2024

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into an exclusive...

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

CareDx Announces IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

  • Erbe Elektromedizin GmbH
  • 03 Dec 2025
Within one year of its launch, L&C Bio

Within one year of its launch, L&C Bio's 'Re2O' has emerged as a leading procedure in K-Medical Tourism

  • L&C BIO Co., Ltd
  • 03 Dec 2025
Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

  • Celltrion
  • 01 Dec 2025
Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

  • Samsung Bioepis Co., Ltd.
  • 01 Dec 2025
Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

  • Menarini Industrie Farmaceutiche Riunite
  • 25 Nov 2025
Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

  • Eisai Inc.
  • 25 Nov 2025
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
December   2025
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31        

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.